Case Report: Treatment of light‐chain amyloidosis with daratumumab monotherapy in two patients
- 11 December 2017
- journal article
- research article
- Published by Wiley in European Journal of Haematology
- Vol. 100 (4), 386-388
- https://doi.org/10.1111/ejh.13008
Abstract
Immunoglobulin light-chain amyloidosis (AL) affects multiple organs, most prominently the kidney and the heart. Renal and cardiac impairment are both associated with poor prognosis and most patients die as a consequence of renal or cardiac failure. Monoclonal antibodies such as daratumumab (human IgG1 anti-CD38) and elotuzumab (anti-SLAMF7) have shown promising efficacy for the treatment of relapsed and refractory multiple myeloma. In this case report we show 2 patients with severe AL, one with severe heart failure and one with heart and renal failure, undergoing treatment with daratumumab. Both patients showed a rapid decrease in FLC in response to daratumumab infusions, with few associated adverse events. Using therapeutic CD38 antibodies as a front-line treatment for AL could induce rapid responses while maintaining a tolerable safety profile in these ultra-fragile patients.Keywords
This publication has 4 references indexed in Scilit:
- Daratumumab yields rapid and deep hematologic responses in patients with heavily pretreated AL amyloidosisBlood, 2017
- First report of safety and efficacy of daratumumab in 2 cases of advanced immunoglobulin light chain amyloidosisBlood, 2016
- A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosisBlood, 2013
- Serum immunoglobulin free light-chain measurement in primary amyloidosis: prognostic value and correlations with clinical featuresBlood, 2010